161 related articles for article (PubMed ID: 36469551)
1. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.
Dong Z; Song JY; Thieme E; Anderson A; Oh E; Cheng WA; Kuang BZ; Lee V; Zhang T; Wang Z; Szymura S; Smith DL; Zhang J; Nian W; Zheng X; He F; Zhou Q; Cha SC; Danilov AV; Qin H; Kwak LW
Blood Adv; 2023 Mar; 7(6):918-932. PubMed ID: 36469551
[TBL] [Abstract][Full Text] [Related]
2. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies
Qin H; Wei G; Sakamaki I; Dong Z; Cheng WA; Smith DL; Wen F; Sun H; Kim K; Cha S; Bover L; Neelapu SS; Kwak LW
Clin Cancer Res; 2018 Mar; 24(5):1114-1123. PubMed ID: 29180606
[No Abstract] [Full Text] [Related]
3. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
[TBL] [Abstract][Full Text] [Related]
4. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
5. BAFF receptor antibody for mantle cell lymphoma therapy.
Zhang K; Roy NK; Vicioso Y; Woo J; Beck R; de Lima M; Caimi P; Feinberg D; Parameswaran R
Oncoimmunology; 2021 Mar; 10(1):1893501. PubMed ID: 33747637
[TBL] [Abstract][Full Text] [Related]
6. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
[TBL] [Abstract][Full Text] [Related]
7. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.
Parameswaran R; Lim M; Fei F; Abdel-Azim H; Arutyunyan A; Schiffer I; McLaughlin ME; Gram H; Huet H; Groffen J; Heisterkamp N
Mol Cancer Ther; 2014 Jun; 13(6):1567-77. PubMed ID: 24825858
[TBL] [Abstract][Full Text] [Related]
8. Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody.
Nakamura N; Hase H; Sakurai D; Yoshida S; Abe M; Tsukada N; Takizawa J; Aoki S; Kojima M; Nakamura S; Kobata T
Virchows Arch; 2005 Jul; 447(1):53-60. PubMed ID: 16025281
[TBL] [Abstract][Full Text] [Related]
9. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
11. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Qin H; Dong Z; Wang X; Cheng WA; Wen F; Xue W; Sun H; Walter M; Wei G; Smith DL; Sun X; Fei F; Xie J; Panagopoulou TI; Chen CW; Song JY; Aldoss I; Kayembe C; Sarno L; Müschen M; Inghirami GG; Forman SJ; Kwak LW
Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554741
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
13. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
14. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
16. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.
Rihacek M; Bienertova-Vasku J; Valik D; Sterba J; Pilatova K; Zdrazilova-Dubska L
Biomed Res Int; 2015; 2015():792187. PubMed ID: 26339644
[TBL] [Abstract][Full Text] [Related]
17. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Herbst R; Wang Y; Gallagher S; Mittereder N; Kuta E; Damschroder M; Woods R; Rowe DC; Cheng L; Cook K; Evans K; Sims GP; Pfarr DS; Bowen MA; Dall'Acqua W; Shlomchik M; Tedder TF; Kiener P; Jallal B; Wu H; Coyle AJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):213-22. PubMed ID: 20605905
[TBL] [Abstract][Full Text] [Related]
19. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
Breton CS; Nahimana A; Aubry D; Macoin J; Moretti P; Bertschinger M; Hou S; Duchosal MA; Back J
J Hematol Oncol; 2014 Apr; 7():33. PubMed ID: 24731302
[TBL] [Abstract][Full Text] [Related]
20. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells.
Rauch M; Tussiwand R; Bosco N; Rolink AG
PLoS One; 2009; 4(5):e5456. PubMed ID: 19421318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]